Clinical features and treatment of 70 children with lupus anticoagulant-hypoprothrombinemia syndrome: a retrospective study from a single center in China

IF 3.4 3区 医学 Q2 HEMATOLOGY
Dandan Tian , Junfeng Zhang , Jintu Lou , Xuejun Chen , Juan Liang , Xiaojun Xu , Hui Gao , Wenjian Nie , Qing Ye , Hongqiang Shen
{"title":"Clinical features and treatment of 70 children with lupus anticoagulant-hypoprothrombinemia syndrome: a retrospective study from a single center in China","authors":"Dandan Tian ,&nbsp;Junfeng Zhang ,&nbsp;Jintu Lou ,&nbsp;Xuejun Chen ,&nbsp;Juan Liang ,&nbsp;Xiaojun Xu ,&nbsp;Hui Gao ,&nbsp;Wenjian Nie ,&nbsp;Qing Ye ,&nbsp;Hongqiang Shen","doi":"10.1016/j.rpth.2024.102577","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) is a rare acquired bleeding disorder characterized by the presence of lupus anticoagulant (LA) and acquired hypoprothrombinemia.</div></div><div><h3>Objectives</h3><div>To summarize the experience of diagnosis, clinical features, and treatment of lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS).</div></div><div><h3>Methods</h3><div>A retrospective study of 70 children diagnosed with LAHPS from January 2019 to February 2024 at a single center was conducted.</div></div><div><h3>Results</h3><div>A total of 70 subjects (32 boys and 38 girls), with a mean age of 5.58 years, were included in the study. Among these subjects, 15 had autoimmune diseases (AIDs), 51 had infections, and 4 had unknown causes. Fifty-six of 70 (80%) subjects experienced bleeding with the median bleeding score of 4, 1 of 70 (1.4%) presented with thrombosis, and 13 of 70 (18.6%) were asymptomatic. All patients exhibited prolonged prothrombin time, significantly prolonged activated partial thromboplastin time, decreased factor (F)II activity (FII:C), and positive lupus anticoagulant. There was a weak negative correlation between the severity of bleeding and FII:C level (<em>rs</em> = −0.4283; <em>P</em> &lt; .001). Patients with infection-associated LAHPS were younger than those with AIDs-associated LAHPS (<em>P</em> &lt; .0001). In the study, LAHPS subjects are treated with corticosteroids as the first-line therapy, or in combination with immunosuppressants. Coagulation factor replacement therapy can effectively prevent and control bleeding events. After follow-up, lupus anticoagulant of all patients had turned negative within 12 weeks. And, prothrombin time and FII:C were completely normalized of all patients without recurrence of bleeding and without thrombosis.</div></div><div><h3>Conclusion</h3><div>Children develop LAHPS most commonly after AIDs and infection. Most patients presented with mild to moderate bleeding. The severity of bleeding symptoms was not exactly parallel to the decreased FII:C level.</div></div>","PeriodicalId":20893,"journal":{"name":"Research and Practice in Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research and Practice in Thrombosis and Haemostasis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2475037924002723","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) is a rare acquired bleeding disorder characterized by the presence of lupus anticoagulant (LA) and acquired hypoprothrombinemia.

Objectives

To summarize the experience of diagnosis, clinical features, and treatment of lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS).

Methods

A retrospective study of 70 children diagnosed with LAHPS from January 2019 to February 2024 at a single center was conducted.

Results

A total of 70 subjects (32 boys and 38 girls), with a mean age of 5.58 years, were included in the study. Among these subjects, 15 had autoimmune diseases (AIDs), 51 had infections, and 4 had unknown causes. Fifty-six of 70 (80%) subjects experienced bleeding with the median bleeding score of 4, 1 of 70 (1.4%) presented with thrombosis, and 13 of 70 (18.6%) were asymptomatic. All patients exhibited prolonged prothrombin time, significantly prolonged activated partial thromboplastin time, decreased factor (F)II activity (FII:C), and positive lupus anticoagulant. There was a weak negative correlation between the severity of bleeding and FII:C level (rs = −0.4283; P < .001). Patients with infection-associated LAHPS were younger than those with AIDs-associated LAHPS (P < .0001). In the study, LAHPS subjects are treated with corticosteroids as the first-line therapy, or in combination with immunosuppressants. Coagulation factor replacement therapy can effectively prevent and control bleeding events. After follow-up, lupus anticoagulant of all patients had turned negative within 12 weeks. And, prothrombin time and FII:C were completely normalized of all patients without recurrence of bleeding and without thrombosis.

Conclusion

Children develop LAHPS most commonly after AIDs and infection. Most patients presented with mild to moderate bleeding. The severity of bleeding symptoms was not exactly parallel to the decreased FII:C level.
70 例狼疮抗凝物-高凝血酶原血症综合征患儿的临床特征和治疗:一项来自中国单一中心的回顾性研究
背景狼疮抗凝物-低凝血酶原血症综合征(LAHPS)是一种罕见的获得性出血性疾病,其特征是存在狼疮抗凝物(LA)和获得性低凝血酶原血症。目的总结狼疮抗凝物-低凝血酶原血症综合征(LAHPS)的诊断、临床特征和治疗经验。方法对2019年1月至2024年2月在一个中心确诊为LAHPS的70名儿童进行回顾性研究。结果共纳入70名受试者(32名男孩和38名女孩),平均年龄为5.58岁。在这些受试者中,15 人患有自身免疫性疾病(AID),51 人患有感染,4 人病因不明。70 名受试者中有 56 人(80%)出现出血,出血中位数为 4 分,70 人中有 1 人(1.4%)出现血栓形成,70 人中有 13 人(18.6%)无症状。所有患者都表现出凝血酶原时间延长、活化部分凝血活酶时间明显延长、因子(F)II 活性(FII:C)降低和狼疮抗凝物阳性。出血严重程度与 FII:C 水平呈弱负相关(rs = -0.4283; P <.001)。感染相关 LAHPS 患者比艾滋病相关 LAHPS 患者更年轻(P < .0001)。在研究中,LAHPS 受试者接受皮质类固醇作为一线疗法,或与免疫抑制剂联合使用。凝血因子替代疗法可有效预防和控制出血事件。经过随访,所有患者的狼疮抗凝物都在 12 周内转为阴性。所有患者的凝血酶原时间和 FII:C 均完全恢复正常,未再发生出血和血栓形成。大多数患者表现为轻度至中度出血。出血症状的严重程度与 FII:C 水平的下降并不完全一致。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.60
自引率
13.00%
发文量
212
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信